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In tissue engineering ﬁelds, recent interest has been focused on stem cell therapy to replace or repair damaged or worn-out
tissues due to congenital abnormalities, disease, or injury. In particular, the repair of articular cartilage degeneration by stem
cell-based tissue engineering could be of enormous therapeutic and economic beneﬁt for an aging population. Bone marrow-
derived mesenchymal stem cells (MSCs) that can induce chondrogenic diﬀerentiation would provide an appropriate cell source
to repair damaged cartilage tissues; however, we must ﬁrst understand the optimal environmental conditions for chondrogenic
diﬀerentiation. In this review, we will focus on identifying the best combination of MSCs and functional extracellular matrices
that provides the most successful chondrogenesis.
1.Introduction
Tissue loss or degeneration caused by congenital abnor-
malities, disease, or injury is of great consequence given
human tissue’s limited intrinsic potential for healing [1].
In particular, articular cartilage shows little or no intrinsic
capacity for repair in response to injury or disease, and even
minor lesions or injuries may lead to progressive damage
and joint degeneration. Currently, frequent treatments, such
as surgical intervention, to repair articular cartilage are
less than satisfactory and rarely restore full function. One
strategy for repairing articular cartilage degeneration via
tissue engineering technologies is to create constructs of cells
placed or injected onto or with matrices [2]. The underlying
principle of tissue engineering (Figure 1(a)) involves the
utilisation of biocompatible and mechanically conductive
scaﬀolds, productive cell sources, and inductive molecules
for the optimal diﬀerentiation and proliferation of the cell
type of interest [3]. In this method, constructsof autologous,
allogeneic, or xenogeneic cells seeded in scaﬀolds, that is,
synthetic extracellular matrices designed to support cell
growth and tissue development, are implanted at a repair site
in the body to promote the diﬀerentiation and maturation of
the cell type of interest (Figure 1(b))[ 4]. In practice, tissue-
speciﬁc cells are often seeded into the scaﬀold ex vivo prior
to transplantation, and with time, the cells synthesise a new
extracellular matrix (ECM) as the scaﬀold produces new,
properly functioning tissue.
For this reason, the appropriate selection of cells and
m a t e r i a l sa ss c a ﬀolds is one of the most important factors
for successful, cell-based cartilage tissue engineering because
the reconstruction and regeneration of damaged tissues
occurs via an ordered pathway of cellular events aﬀected
by biological and mechanical factors [5, 6]. For clinical
applications,autologousorallogeneiccellgraftsaregenerally
used. Autologous grafts are ideal, but they are often limited
by the availability of donors [7]. Moreover, xenogeneic grafts
are frequently subject to rejection as antigens present may
elicit an immune reaction in the recipient and are further
limited by pathogens found in the donor tissue. However,
the use of allogeneic grafts is clinically routine due to the
development of immunosuppressive drug therapies, such
as cyclosporine, FK506, and rapamycin. Stem cells have
the potential to be applied as a prepared allogeneic graft,
therebyavoidingtheneedfortissueharvestingofprospective
recipients, an extraordinary therapeutic advantage for many
cell types. They have the capacity for self-renewal and the
ability to generate diﬀerentiated cells. Recently, the ﬁeld of
stem cell biology has attracted more attention because of the
isolation of human embryonic stem cells (ESCs), and the2 Journal of Biomedicine and Biotechnology
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Figure 1: Tissue engineering strategy. (a) Basic principles of tissue
engineering. (b) General methods of cell culture using a scaﬀold.
suggestionthatadultstemcellsmayhaveabroaderpotential,
that is, plasticity, than was previously thought [8].
ESCs derived from totipotent cells of an early mam-
malian embryo can proliferate indeﬁnitely and can give rise
to virtually any cell type. Therefore, the use of ESCs to
replace damaged cells and tissues promises future hope for
the treatment of many diseases. However, many countries
now face complex ethical and legal questions as a result
of the research to develop these cell therapies [9]. To
circumvent these problems, many attempts have been made
to isolate adult stem cells from mammalian tissues [10]. In
particular, the adult bone marrow contains mesenchymal
stem cells (MSCs), which contribute to the regeneration
of mesenchymal tissues, such as bone, cartilage, muscle,
ligament, tendon, adipose, bone marrow stroma, and other
connective tissues [11, 12] and may be obtained from
patients using minimally invasive techniques such as a bone
marrow biopsy.
In this review, we will focus on the use of synthetic
polymeric scaﬀolds in articular cartilage therapy and discuss
the strategies for speciﬁc targeting. In particular, we will
describe the potential use of MSCs to deliver these scaﬀolds.
2. MSCs for Cartilage Repair
In cell-based tissue engineering ﬁelds, selection of the
source cells is required for consideration of several cri-
teria, including ease of access and availability, a capacity
for diﬀerentiation, and a lack of minimal immunogenic
or tumourigenic ability. For cartilage repair in cell-based
tissue engineering applications, source cells have included
committed chondrocytes, ESCs, and adult stem cells. Each
celltypehasitslimitationsandadvantagesduetoitsintrinsic
biological properties. However, chondrocytes have shown
limited rediﬀerentiation capability after in vivo expansion
in clinical trials and in tissue engineering applications.
Moreover, ESCs and their unwanted diﬀerentiations, such
as tumour formations, are associated with ethical and legal
concerns and are thereby an unsuitable cell source in
basic research and clinical applications, despite the inﬁnite
pluripotentiality of ESCs. However, adult stem cells derived
from various adult tissues have emerged as promising cell
sources [11].
Amongtheadultstemcells,speciﬁcallymultipotentadult
stem cells, MSCs are considered to be the cell type of choice
for cell-based cartilage tissue engineering because of (1) the
ease with which they can be isolated and expanded and
(2) their multilineage diﬀerentiation capabilities [13]. The
isolation of these cells from adult tissues raises opportunities
for the development of novel cellular therapies without the
ethical considerations associated with ESC usage. Because of
their multipotentiality and capacity for self-renewal, unlike
ESCs, MSCs may represent units of active regeneration for
damaged cartilage [14].
Although MSCs have shown great promise in cartilage
repair and regeneration, several requirements should be
e xaminedt oallo wthemt oeﬀectivelydiﬀerentiateintochon-
drocytes and maintain this diﬀerentiated phenotype prior to
implantation or delivery. These would involve the methods
and materials for culture conditions of MSCs to repair or
restore full functions of damaged cartilage. Upon proper
culture conditions containing certain exogenous factors,
MSCs can be directed towards chondrogenic diﬀerentiation.
Growthfactorsthatpromotechondrogenesisordemonstrate
a chondrogenic eﬀect both in vivo and in vitro include
bone morphogenetic proteins (BMPs), transforming growth
factor-β (TGF-β), and insulin-like growth factors [15–17].
BMPs are secreted molecules of the TGF-β superfamily
of growth and diﬀerentiation factors that were originally
detected in and puriﬁed from demineralised bone [18].
BMPs have been shown to function as key regulators in
cartilage and bone development [19–22] and to function in
repair and remodelling of the adult skeletal system [23–25].
These ﬁndings also provide crucial insights into cartilage
repair and regeneration as the progression of osteoarthritis
is always accompanied by damage to the subchondral bone
and the formation of osteophytes. Despite many advances in
propercultureconditionsforMSCs,mostofthemethodsare
limitedtoatwo-dimensional(2D)culture,andmostofthem
provide little information about the proper chondrogenic
induction of MSCs in three-dimensional (3D) culture.
3. MSC-Based CartilageTissueEngineering
The 3D culture system for cell diﬀerentiation and prolif-
eration may improve our understanding of the structure-
function relationship under both normal and pathological
conditions. With regard to cell-based cartilage tissue engi-
neering, successfullyreconstructed cartilage tissue formationJournal of Biomedicine and Biotechnology 3
would be structurally reunited with the peripheral cartilage
and would suggest biomechanical properties necessary for
permanence and eﬃcacy under 3D environmental condi-
tions [26, 27]. It is currently accepted that 3D behaviours of
speciﬁc cells, including MSCs, are quite diﬀerent from 2D
behaviours, indicating that 3D in vitro culture systems can
mimic the in vivo situation more closely than 2D cultures
[28–30].
3.1. Design of ECM. The successful outcome of cell-based
cartilage tissue engineering using a 3D culture of MSCs
ultimately depends on the design of synthetic artiﬁcial ECMs
for the proper diﬀerentiation of MSCs into chrondrocytes
[31] because speciﬁc stem cells alone face obstacles in the
construction of cartilage formation. For the development
of viable cartilage formation, synthetic ECMs should be
designed considering a number of requirements, namely,
mechanical properties such as a capability to withstand the
large contact stresses and strains of an articulating joint,
allow functional tissue growth, and provide appropriate cell-
matrix interactions to stimulate tissue growth [32, 33]. One
challenge for these solutions is the delivery of stem cells to
the targeted tissue without cell loss. Delivery of stem cells
a l o n em a yn o tb es u ﬃcient to restore damaged tissues as
a result of enormous cell loss after delivery. Furthermore,
little is known regarding the optimal delivery strategy for
stem cells. Increasing the eﬃciency of MSC delivery and
targeting the infused cells to speciﬁc tissue locations could
have a large impact on the therapeutic uses of MSCs to treat
diseases [12]. The delivery of MSCs can be achieved using
injectable matrices, soft scaﬀolds, membranes, solid load-
bearingscaﬀolds,orimmunoprotectivemacroencapsulation.
Thus, to expand their clinical potential, next generation
therapies will depend on smart delivery concepts that make
use of the regenerative potential of MSCs, morphogenetic
growth factors, and biomimetic materials.
Other challenges are associated with the biomaterial
scaﬀolds designed to guide tissue growth and diﬀerentiation.
These biomaterials must meet several criteria to maximise
the chances of a successful repair, including biodegrad-
ability and/or biocompatibility, facilitating functional tissue
growth, and appropriate biomechanical properties [34–
36]. Biomaterials used for cartilage tissue engineering can
have the form of cell-entrapped scaﬀolds with nano- or
microstructures [30, 37, 38].
3.2. Biomaterial Scaﬀolds. Polymercross-linked scaﬀolds
have been used for cell entrapment in cell-based tissue
engineering applications, due to their 3D networks, tissue-
like water content, structure stability, and biocompatibility
[30, 40]. There are a number of candidate scaﬀolding
materials that include natural polysaccharides and proteins,
such as alginate and collagen, and synthetic polymers, such
as polyethylene glycol (PEG), poly(ε-caprolactone) (PCL),
polyglycolic acid (PGA), polylactic acid (PLA), and poly
(D,L-lactide-co-glycolide) (PLGA) [41]. Although tissue-
engineered constructs are well designed for 3D culture,
maintaining the chondrogenic phenotype is problematic
when culturing MSCs alone on the scaﬀolds, that is, without
other local factors in vivo. To overcome these problems,
a number of novel biomaterials, innovative cell culture
techniques, and newly discovered growth factors should
be utilised according to directions from cell-based tissue
engineering applications. In particular, growth factors are
local factors that are key regulators for proper diﬀerentiation
of MSCs in research and clinical applications.
For long-term retention of cells in vivo, the cells should
be contained within the inner structures of the scaﬀold.
With a proper fabrication method, porous scaﬀolds can
help cells to penetrate into the scaﬀold when implanted
into the body [42, 43]. One of the basic problems from a
scaﬀold design point of view is that to achieve signiﬁcant
strength, the scaﬀold material must have suﬃciently high
interatomic and intermolecular bonding, but must have at
the same time a physical and chemical structure which
allows for hydrolytic attack and breakdown. For example,
PCL as the scaﬀold material degrades relatively slowly and
possesses an appropriately high bulk stiﬀness to facilitate
MSC diﬀerentiation toward skeletal lineages [44]. The PCL
scaﬀold was used after loading TGF-β3p h y s i c a l l yc o m p l e x e d
with chondroitin sulfate (CS) [45], because it was designed
to maintain an interconnected pore network for at least 6
months, and the neocartilage would have suﬃcient time to
mature without biomechanical overload [46].
In addition to porous scaﬀolds, the biofunctional con-
structs have been developed for better chondrogenesis of
MSCs. In the application of cartiliage formation in the
research ﬁeld, for instance, fully thermoreversible gelling
polymers have attracted considerable attention for use as
scaﬀold materials to hold cells in situ [47]. Na et al.
developed poly(N-isopropylacrylamide) (PNIPAAm)-based
hydrogel scaﬀolds to investigate their capability to deliver
a mixture of MSCs and growth factors for the better
induction of chondrogenic diﬀerentiation [48, 49]. These
thermoreversible hydrogel scaﬀolds can revert from solid to
liquid state and from liquid to solid state without abrogating
their intrinsic properties. These scaﬀolds were completely
soluble in aqueous solutions at temperatures below their
lower critical solution temperature (LCST), but they solidify
at temperatures above their LCST, forming a hydrated gel
[49, 50]. However, its clinical application is limited due to its
nonbiodegradability. Therefore, the design of biodegradable
scaﬀolds, which have biofunctions as well as mechanical
strength for eﬀective chondrogenesis of MSCs, is required to
overcome the issues. The ideal scaﬀold has suﬃcient strength
to protect cells from compression and shearing forces, while
still having injury site anchoring potential and porosity to
allow nutrient and diﬀerentiation factors to diﬀuse through
it. The scaﬀold must also degrade at a rate that optimizes
cellular growth and tissue regeneration. Such ideal scaﬀolds
have not yet been designed. The optimal time point for
evaluationofascaﬀold-basedtreatmentisalsocritical,which
depends on the scaﬀold, cells, and tissue in question [51].
Biodegradable micro- and nanocomposite materials that
can provide the appropriate strength, integrate the desirable
biological cues, and provide for the controlled sequential
delivery of multiple growth factors would help fulﬁll the4 Journal of Biomedicine and Biotechnology
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Figure 2: (a) Diagram of heparinized nanoparticles coated onto PLGA microsphere for stem cell delivery. (b) The SEM images of PLGA
microspheres (upper (left) and bottom (right)) fabricated with heparin/poly(l-lysine) nanoparticles [37].
promise of regenerative medicine. Also the development
of relevant scaﬀold design using suitable biomaterials and
incorporation of appropriate biomolecules and the selection
of cell types plays a vital role in tissue repair. Recent
conceptualadvances,whichhavetakenadvantageofnewand
practical techniques for size distribution and stabilisation
control, have created novel routes for the synthesis of
nanoparticle-basedmaterials,inwhichnanoparticlebuilding
blocks can be spatially ordered in a controlled manner
[37]. Polyionic complexed nanoparticles are composed of
heparin and poly(l-lysine) as a stem cell-delivery system,
as depicted in Figure 2(a). Heparin-functionalised hydrogel
supported MSC viability and induced chondrogenic diﬀer-
entiation. Negatively charged heparin is widely used in the
biomaterial ﬁeld because it can interact with a variety of
proteins that have heparin-binding domains, including var-
ious growth factors that enable the growth factors to cross-
link their receptors. Additionally, poly(l-lysine) has been
commonly used as a model cationic polymer to fabricate the
polyionic complexes with anionic polymers. Heparin/poly(l-
lysine) nanoparticles formed a polyelectrostatic layer-by-
layer assembly and were sequentially immobilised on PLGA
microspheres as microcarriers of MSCs. The heparin/poly(l-
lysine) polyelectrolyte complex is highly distributed on the
PLGA microspheres. PLGA is known as the scaﬀold material
to easily form nano- or microstructured particles which can
entrap cells or load small molecules due to its excellent
biocompatibility, degradability, and processibility [52]. The
speciﬁc binding activity of heparin in the bioconjugate is
not reduced in the immobilisation process results, which
may be due to the presence of heparin within the outer
shell of the nanoparticles on the surfaces of the PLGA
microspheres (Figure 2(b)). As shown in the SEM images,
the heparin/poly(l-lysine) electrolyte complex is heavily
distributed on the PLGA microspheres.
In another example using the nanoconstructs composed
of ﬁbrin hydrogels containing MSCs mixed with heparinised
BMP-2, the bioactivities of entrapped MSCs mixed with
growth factors were maintained for long term [30]. More-
over, PLGA microspheres can be used as cell delivery vehicles
for controlled release of cells mixed with small molecules,
which can help MSCs enhance their bioactivities. Park et al.
reported the dual delivery of TGF-β3 and dexamethasone
from transplanted PLGA constructs in vivo to engineer
inﬂammation-free and cartilage-associated tissue [38].
Although PLGA has proved to be an excellent material
for cartilage tissue engineering due to its biodegradable
properties, mechanical strength, and ease of fabrication
into a considerably complex formation, the principle usage
of PLGA as a delivery vehicle has problems as it does
not oﬀer a desirable environment for cell adhesion due
to its limitation of binding sites mediated by biological
recognition and high hydrophobicity. Based upon an early
fundamental step in which positive cell-substrate interac-
tions enable cell proliferation, migration, and diﬀerentiation
on the surface of materials, many studies have focused
on modifying the matrix surface in an eﬀort to increase
cell-substrate interaction for cell delivery [53–55]. BindingJournal of Biomedicine and Biotechnology 5
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Figure 3: Schematic diagram of RGD-modiﬁed PLGA microspheres containing growth factors and dexamethasone. Using a layer-by-layer
(LBL) technique, positively charged, PEI precoated PLGA microspheres coated with negatively charged RGD molecules were fabricated for
hMSC delivery and regeneration of injured tissues. The combination of growth factors, DEX, and RGD was an eﬀective scaﬀold for cell
delivery and diﬀerentiation of embedded hMSCs [39].
sites in ﬁbronectin, osteopontin, collagens, ﬁbrinogen, and
thrombospondin that contain the tripeptide Arg-Gly-Asp
(RGD) are easily recognised by mammalian cells. The RGD
sequences of the adhesive proteins are recognised by a
structurally related receptor family, that is, integrins, which
bind to RGD on the surface of cells, allowing cells to adhere
[42, 56, 57]. The incorporation of bioactive motifs such
as RGD may be the best adapted strategy to enhance cell
adhesion [58–60]. As 3D scaﬀolds have a larger surface area
and highly interconnected porous structures with suitable
porosity and pore size, modiﬁcation of the scaﬀold surface
to improve the interaction between cells and the surface
would have a greater potential for tissue engineering [39, 61–
65]. A promising strategy is to immobilise RGD peptides on
scaﬀold surfaces by evaluating embedded MSC behaviours,
including attachment, cellular distribution, signal transduc-
tion, and survival on the modiﬁed surface. For instance,
PLGA microscaﬀolds conjugated with RGD peptides were
constructed as an MSC-delivery vehicle (Figure 3). The
regulation of stem cell diﬀerentiation by adhesion molecules
and growth factors has the potential to enable the formation
of therapeutic vehicles for the delivery of MSCs that are
easily fabricated, less expensive, and more easily controlled
than currently available delivery systems. The embedded
MSCs easily adhered onto PLGA microspheres mediated by
the RGD peptide, proliferated well onto the scaﬀolds and
diﬀerentiated to perform distinct functions [66].
Culture methods are deeply considerable to improve the
chondrogenetic potential of MSCs, because MSCs markedly
decrease with the increase of passage number. If cultured in
a medium that is not supplemented with factors facilitating
the maintenance of plural diﬀerentiation potential, MSCs
can hardly diﬀerentiate into chondrocytes after repeated
passages. Some strong inductive signals for chondrogenesis
are required to diﬀerentiate the passage-cultured MSCs into
chondrocytes [67]. Coculture of MSCs with mature chon-
drocytes is a strategy that both provides inductive signals
and solves the cell source problem. Coculture techniques
of MSCs and autologous chondrocytes are frequently used
to improve induction of the chondrogenic diﬀerentiation of
MSCsinsteadofincludinggrowthfactorsintheMSCculture
[68, 69], because the chondrogenic diﬀerentiation of MSCs
induced by growth factors exhibits some defects, including
an instability of the chondrocyte phenotype and a lack of
ECM secretion [70]. In the 3D hydrogel constructs, Cocul-
ture with autologous chondrocytes and MSCs can show a
signiﬁcantly higher number of speciﬁc lacunae phenotypes
[68, 71]. Chondrocytes express soluble growth factors that
can help MSCs selectively promote chondrogenesis, and this
selective eﬀect is not mimicked by an exogenously added
growth factors.
In addition, transfection of MSCs with growth factor
genes has been proposed and practiced. However, the
outcomes are not completely desirable not only due to the
damage caused by the invasive procedure of transfection but
also because long-term overexpression of a growth factor
may result in undesirable changes in the transfected cells.
To overcome these challenges, eﬀective chondrogenesis in6 Journal of Biomedicine and Biotechnology
MSCs can be achieved by coculturing them with autologous
chondrocytes transfected with growth factor genes [72].
This gene transfected Coculture system can avoid directly
transfecting MSCs, but instead transfers growth factor genes
to their Cocultured chondrocytes.
4. FinalRemarks andFurther Researches
The clinical need for cartilage repair technologies is unmis-
takable. Many people over the age of 40 suﬀer from
degeneration or injury of their cartilage, leading to a
reduced workforce and increased medical expenses. Thus,
improvements in cartilage repair using a cell-based tissue
engineering approach will greatly beneﬁt public health
and the economy. Personalised cell therapy for cartilage
repairusingcell-basedtissueengineeringtechnologieswould
provide clinically practical methods for producing a cartilage
tissue equivalent. A number of biomaterials are available
as scaﬀolds, and research continues to help us understand
more details about how tissues develop and which cell type
shouldbeapplied.Thesestudieshaveprovideddetailsofhow
tissues grow in vitro and in vivo, but clinical applications
depend on working with surgeons and the translation of
these materials and technologies to in vivo models that are
more relevant to patients. When cell-based cartilage tissue
engineering technologies are applied to new animal models,
we attempted to ﬁnd better functional compositions for suc-
cessful applications than were observed in previous studies.
Althoughstemcell-basedcartilagetissueengineeringsystems
may demonstrate success even in animal models, there are
a number of new challenges when the technologies are
applied to humans. Further research on in vivo application
must address immunological issues, integration of host and
stem cell-based engineered cartilage, and the variability of
tissue development in an in vivo environment, depending
on surrounding disease processes, age, or physical activity.
Therefore, interdisciplinary studies are not only necessary
but crucial before cell-based cartilage tissue engineering can
reach its full potential in cartilage repair and regeneration.
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